Circulating tumor cells in prostate cancer: A better predictor of survival than prostate specific antigen? - Abstract

Prostate specific antigen has been extensively studied and represents the most common biomarker across the spectrum of prostate cancer.

Circulating tumor cells are a more recent method for monitoring patients with metastatic prostate cancer and have shown great promise in predicting outcomes. We review the prognostic capabilities of these markers to determine if circulating tumor cells should unseat prostate specific antigen as the test of choice in prostate cancer.

Written by:
Hu B, Goldkorn A.   Are you the author?
Institute of Urology, Keck Medical Center of USC, University of Southern California, Los Angeles, CA, USA.

Reference: Expert Rev Anticancer Ther. 2014 Sep 9:1-4.
doi: 10.1586/14737140.2014.957190


PubMed Abstract
PMID: 25199875

UroToday.com Prostate Cancer Section

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe